Tyler’s Latest Columns

  1. Optimism For Biopharma In 2025 12/27/2024

    In this closing segment from the executive roundtable discussion, our panelists express their confidence in the industry's mission and maintain a positive outlook for the years ahead.

  2. How Biotechs Can Navigate Market Uncertainty In 2025 12/27/2024

    In this segment of the executive roundtable discussion, our panelists weigh in on how to prepare for what may be a challenging financial climate in 2025. 

  3. Political Influences And Regulatory Implications For Biotech In 2025 12/27/2024

    In this segment of the executive roundtable discussion, our panelists discuss the changing political landscape and its potential effects from a regulatory and economic point of view.

  4. 2025 Predictions For AI Use In Biotech 12/26/2024

    In this segment of the executive roundtable discussion, our panelists discuss the growing prevalence of AI and its implications, both good and bad. They share their thoughts on smart adoption and the need for regulatory guidance moving forward.

  5. Cell Therapy Manufacturing Trends And Advancements Continuing In 2025 12/26/2024

    In this segment of the executive roundtable discussion, our panelists reflect on recent advances in cell therapy manufacturing and discuss active areas of innovation.

  6. Exciting Areas Of Innovation For Cell Therapies 12/23/2024

    In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.

  7. Leveraging Directed Evolution To Optimize AAV Vector Design 12/18/2024

    4D Molecular Therapeutics (4DMT) CEO and co-founder, David Kirn, MD, talks about the company’s approach to vector optimization, its product development, and its stage-appropriate buildup of internal GMP manufacturing.

  8. Coya Therapeutics On Developing A Combination Biologic 10/31/2024

    Coya Therapeutic’ executive chairman, Howard Berman, Ph.D., discusses the company's approach to developing a combination biologic and the challenges that multi-targeted therapeutics present.

  9. Inside J&J's Many-Indication mAb 10/30/2024

    Leona Ling, Ph.D.’s relationship with the investigational monoclonal antibody nipocalimab is defined by curiosity, perseverance, and commitment. She discovered the molecule while working for Momenta Pharmaceuticals, and she continues to shepherd it long after J&J's $6.5 billion bid for it in 2020.

  10. Tune Therapeutics On Clinical Readiness, Technology Adoption 10/16/2024

    Heidi Zhang, Ph.D., explains Tune Therapeutics' epigenetic approach to gene therapy and how the company is preparing its lead candidate for the clinic, as well as it's modular approach to automation.